Accessibility Menu
Hls Therapeutics logo

Hls Therapeutics(TSX) HLS

Current PriceCA$4.19
Market CapCA$131.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-61%
5 Year-75%
1 Year-14%
1 Month-6%
Hls Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 4.212026-07-22
Hls Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.24%CAD 4.202026-07-15
1 month-5.82%CAD 4.472026-06-22
3 month-9.46%CAD 4.652026-04-23
Year to date-12.66%CAD 4.822025-12-31
1 year-14.26%CAD 4.912025-07-22
3 year-31.54%CAD 6.152023-07-21
5 year-74.9%CAD 16.772021-07-23
Since inception-61.11%CAD 10.822018-03-15

Hls Therapeutics Financials at a Glance

Market Cap

CA$131.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$55.76M

Net Income (TTM)

-$10.27M

EPS (TTM)

-CA$0.45

P/E Ratio

-9.31

Dividend

CA$0.00

Beta (Volatility)

0.50 (Low)

Price

CA$4.19

Volume

364

Open

CA$4.15

Previous Close

CA$4.21

Daily Range

CA$4.15 - CA$4.19

52-Week Range

CA$4.00 - CA$5.77

Estimated Earnings Date

Aug 13, 2026

HLS News

A couple administering a blood pressure test

This Pharmaceutical Company Just Got a Major Boost

Jeffrey LittleAug 27, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hls Therapeutics

HLS Therapeutics Inc. is a specialized pharmaceutical company focused on acquiring and commercializing medicinal products in the central nervous system (CNS) and cardiovascular (CV) sectors. The company operates in Canada, the United States, and international markets, offering a range of innovative therapies.

Products and Services
  • Clozaril, an atypical antipsychotic for schizophrenia treatment
  • Vascepa, an icosapent ethyl capsule formulation for cardiovascular health
  • PERSERIS, an injectable risperidone product for schizophrenia
Growth Outlook
  • Recent quarterly revenue reached CAD 12.65 million, indicating strong market demand
  • Gross profit margin improved to 36.12% in Q1 2026, reflecting operational efficiency
  • Expansion into international markets is expected to drive future revenue growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 54.5 million demonstrates consistent performance
  • Operating cash flow of CAD 6.36 million in Q1 2026 indicates healthy cash generation
  • Current ratio of 1.00 suggests adequate liquidity to meet short-term obligations
HLS Therapeutics Inc. has established itself as a key player in the pharmaceutical industry, particularly in the CNS and CV sectors. The company's diverse product portfolio, including well-known medications like Clozaril and Vascepa, positions it favorably for future growth. Recent financial performance highlights, such as a significant quarterly revenue and improved gross profit margins, underscore the company's operational efficiency and market demand. With a focus on expanding into international markets, HLS Therapeutics is poised for continued growth and success in the pharmaceutical landscape.
AI Generated • Jul 9, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

85

CEO

Craig Millian, MBA

Website

www.hlstherapeutics.com

Headquarters

Etobicoke, ON M9W 6L2, CA

HLS Financials

Key Financial Metrics (TTM)

Gross Margin

61.69%

Operating Margin

-7.34%

Net Income Margin

-18.42%

Return on Equity

-16.54%

Return on Capital

-3.75%

Return on Assets

-7.82%

Earnings Yield

-10.74%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$131.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

31.27M

Volume

364

Avg. Volume

34.80K

Financials (TTM)

Gross Profit

$34.41M

Operating Income

-$4.09M

EBITDA

$17.79M

Operating Cash Flow

$19.89M

Capital Expenditure

-$1.78M

Free Cash Flow

$18.11M

Cash & ST Invst.

$12.33M

Total Debt

$43.96M

Hls Therapeutics Performance Analysis

Hls Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 80,021,0286.4%
20232023-12-31USD 85,130,1566.4%
20242024-12-31USD 77,565,855-8.9%
20252025-12-31USD 77,549,515-0.0%
Hls Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3012.3%
Q32025-09-30-4.7%
Q42025-12-3114.2%
Q12026-03-31-18.0%
Hls Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9585.4%
20232023-12-31USD -1.1521.6%
20242024-12-31USD -0.85-26.6%
20252025-12-31USD -0.55-34.9%
Hls Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3035.7%
Q32025-09-30-33.3%
Q42025-12-3163.9%
Q12026-03-31-65.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$12.65M

+0.2%

Gross Profit

$4.57M

-55.3%

Gross Margin

36.12%

N/A

Market Cap

CA$131.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$1.55M

N/A

Employees

85

N/A

Net Income

-$2.26M

+49.1%

EBITDA

$3.27M

+11.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.33M

-30.4%

Total Debt

$43.96M

-31.0%

Accounts Receivable

$8.14M

+16.6%

Inventory

$7.37M

-1.5%

Long Term Debt

$39.24M

-32.4%

Short Term Debt

$4.72M

-17.1%

Return on Assets

-7.82%

N/A

Return on Invested Capital

-3.99%

N/A

Free Cash Flow

$5.98M

+69.9%

Operating Cash Flow

$6.37M

+79.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RX.VBioSyent Inc.
CA$14.55+0.07%
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
CRDL.TOCardiol Therapeutics Inc.
CA$1.80-1.10%
XLY.TOAuxly Cannabis Group Inc.
CA$0.19+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.62-0.21%
AALAmerican Airlines Group
$13.62-0.08%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.81-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.38+0.04%

Questions About HLS

What is the current price of Hls Therapeutics?

Hls Therapeutics is trading at CA$4.19 per share.

What is the 52-week range for Hls Therapeutics?

Over the past 52 weeks, Hls Therapeutics has traded between CA$4.00 and CA$5.77.

How much debt does Hls Therapeutics have?

As of the most recent reporting period, Hls Therapeutics reported total debt of $61.31M.

How much cash does Hls Therapeutics have on hand?

Hls Therapeutics reported $17.20M in cash and cash equivalents in its most recent financial results.

What is Hls Therapeutics’s dividend yield?

Hls Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services